# GPT 5.2 Review - Reviewer 2/3 (Parallel)

**Model:** gpt-5.2-2025-12-11
**Paper:** paper.pdf
**Reasoning effort:** medium
**Timestamp:** 2026-01-24T10:36:50.889220
**Review mode:** Parallel (3 independent reviewers)
**Response ID:** resp_06553d6e08fba58d0069749220cf8c819fb82b9af6e8bf1f9b
**Tokens:** 8208 in / 5866 out
**Response SHA256:** fd9463f479582cc0

---

## Referee Report (Top General-Interest Journal Standard)

### Paper: “Dental Therapy Authorization and Oral Health Access: Evidence from Staggered State Adoption” (APEP WP 74, Jan 2026)

The paper asks an important policy question—whether authorizing dental therapists improves population-level dental access—and uses modern staggered-adoption DiD (Callaway–Sant’Anna). The headline result is counterintuitive: authorization is associated with *lower* adult dental visit rates. While the topic is high value, the current design and evidence are not yet at the standard required for AER/QJE/JPE/ReStud/Ecta or AEJ:EP. The biggest issues are (i) thin time-series support (biennial 2012–2020 gives only 5 periods), (ii) severe contamination by 2020/COVID and implementation lags, (iii) weak ability to assess pre-trends (often effectively one pre period), and (iv) inference with few treated clusters and an outcome that is itself a noisy estimate.

Below I provide a rigorous format check, a hard methodology/inference assessment, and detailed suggestions.

---

# 1. FORMAT CHECK

### Length
- **Fail for top journal expectations.** The excerpt shows **~18 pages total**, with **References starting ~p.15** and appendices through ~p.18. That implies **~14 pages of main text**, far below the **25+ page** norm for general-interest outlets (excluding refs/appendix).
- For AEJ:EP, shorter papers can sometimes pass, but **not at ~14 pages** given the complexity (policy adoption, endogeneity, staggered DiD, limited periods).

### References
- **Insufficient breadth** for a top-journal empirical DiD paper. You cite Callaway–Sant’Anna (2021) and Goodman-Bacon (2021), which is necessary, but you omit several now-standard references on event studies, inference with few treated units, and robustness to violations of parallel trends. Domain literature is also thin (largely reports/case studies).

### Prose (paragraphs vs bullets)
- Major sections are mostly paragraphs (Intro, Discussion), but there are **prominent bullet lists** in substantive sections:
  - Scope of practice list (Section 2.2, ~p.4).
  - Threats list (Section 4.4, ~p.9).
- Bullet lists are fine in Data/Methods for variable definitions, but here they replace narrative exposition in core conceptual sections. For a top journal, I would rewrite these into paragraphs with citations and mechanisms.

### Section depth (3+ substantive paragraphs per major section)
- **Introduction (Section 1)**: has multiple paragraphs; OK.
- **Background (Section 2)**: subsections exist but are relatively short; some content is list-like.
- **Data (Section 3)**: adequate, but not deep (would benefit from more on measurement, BRFSS comparability, and 2020).
- **Empirical Strategy (Section 4)**: relatively thin for such a design; needs more on weighting, aggregation, and inference.
- **Results (Section 5)**: short; relies on a single outcome and one main table.
- **Discussion (Section 6)**: conceptually fine, but would need more disciplined linkage to identification threats.

### Figures
- Figure 1 and Figure 2 have axes and visible data.
- **Figure 3 (Appendix A, ~p.17) appears extremely small/illegible** (tiny panels, hard-to-read labels). For publication quality, it needs redesign (larger panels, consistent y-axis, readable treatment markers).

### Tables
- Tables have real numbers (no placeholders), but Table 1 includes “—” entries for cohorts not used (fine).
- **However, there is no regression/effect table with cohort-time ATTs**, and no table showing robustness beyond the second comparison group.

---

# 2. STATISTICAL METHODOLOGY (CRITICAL)

### (a) Standard Errors for every coefficient
- **Partial pass.** The main ATT is reported with **SE** (Table 3, ~p.12–13): e.g., ATT = −0.013, SE = 0.006.
- Event-study coefficients appear only in a figure with CI shading; **the paper does not tabulate event-time coefficients with SEs**. Top journals usually require a table or appendix table with exact estimates/SEs.

### (b) Significance testing
- **Pass for the main estimate** (p-values shown in Table 3).
- But you should also provide **t-stats or p-values for key event-time post coefficients** (not only a plot).

### (c) Confidence intervals
- **Pass for the main estimate** (95% CI in Table 3).
- Event study has 95% CI shading; still should tabulate.

### (d) Sample sizes (N)
- **Pass at a high level**: N=245 state-years is reported (Table 3 notes; Section 3.3).
- But **you do not report effective sample size / weights / precision issues**: your outcome is a *state-level estimate* from survey data. There is heteroskedasticity due to varying BRFSS state sample sizes; you should either (i) use microdata and survey weights, or (ii) do precision-weighted estimation and propagate measurement error.

### (e) DiD with staggered adoption
- **Pass** on the core estimator choice: Callaway–Sant’Anna and avoiding already-treated controls is appropriate (Section 4.2).
- However, **execution details are under-specified**:
  - What exact CS aggregation is used (simple ATT, group-size weights, outcome variance weights)?
  - Are you using **DR** or **IPW** versions?
  - What covariates (if any) are included? As written, it appears **unconditional**.

### (f) RDD
- Not applicable (no RDD used).

### Critical inference concern (not addressed)
Even though you report clustered SEs, the design has **very few treated clusters (9 treated states)** and staggered timing with only **5 periods**. Conventional cluster-robust SEs can be unreliable. A top journal will expect:
- **Wild cluster bootstrap** p-values (state-clustered) or randomization inference.
- Methods for inference with **few treated groups** (see Section 4 below for missing citations).

**Bottom line on methodology**: The paper is *not* unpublishable for missing inference (you do report SE/p/CI), but it is **not yet credible at a top-journal level** because the inference strategy is not adequate for few treated units and because the outcome is noisy and 2020 is a major confound.

---

# 3. IDENTIFICATION STRATEGY

### Credibility
Your identifying assumption is parallel trends in untreated potential outcomes. The paper claims pre-trends are fine (p=0.12; Section 5.2, ~p.11–12). But the design provides **very weak support for this**:

1. **Only five time periods (2012, 2014, 2016, 2018, 2020)**.  
   - For Maine (2014 cohort), you effectively have **one pre-period** (2012).  
   - For Vermont (2016), you have at most two pre points.  
   - For 2018 and 2020 cohorts, pre windows exist but are short.

2. **Your pre-trends test is essentially based on a single lead (t = −4)** (Section 5.2 notes this explicitly). A joint test with 1 df is not very informative.

3. **COVID in 2020 is a first-order confound.**  
   Dental visits in 2020 were heavily affected by shutdowns and heterogeneous state policies. Your treatment cohorts include 2020 adopters (OR, WA) and you also measure post for 2018 adopters in 2020. Without a careful strategy, the negative ATT could be largely “authorization × pandemic timing/policy” rather than dental therapy effects.

4. **Implementation timing is mismeasured.**  
   Authorization does not equal practice. Many states authorized but did not have trained/licensed therapists for years. This creates a classic “treatment misclassification” problem that will bias effects toward zero or create spurious dynamics depending on adoption correlated with underlying trends.

### Placebos / robustness
- Only one robustness check is reported (alternative comparison group; Appendix B, ~p.17).
- For a top journal, you need substantially more:
  - Excluding 2020 entirely (estimate on 2012–2018 only).
  - Placebo “fake adoption years.”
  - Sensitivity to alternative cohort mapping (e.g., treat 2019 adopters as treated in 2019 using annual data).
  - Alternative outcomes (cost-related unmet dental care; ED dental visits; Medicaid dental claims where available).
  - Heterogeneity checks (rural, low-income, uninsured)—these are exactly the populations dental therapy targets.

### Do conclusions follow?
The discussion is appropriately cautious (reverse causality, compositional change), but the current evidence **does not allow a causal interpretation** strong enough for a general-interest journal. At present, the paper estimates a reduced-form association that could easily be driven by:
- pandemic shocks,
- endogenous timing,
- or measurement/aggregation choices.

---

# 4. LITERATURE (Missing references + BibTeX)

### Methods literature that should be cited/engaged
You cite Callaway–Sant’Anna and Goodman-Bacon. For a modern DiD/event-study paper, you also need:

1) **Sun & Abraham (heterogeneous treatment effects in event studies)**
```bibtex
@article{SunAbraham2021,
  author  = {Sun, Liyang and Abraham, Sarah},
  title   = {Estimating Dynamic Treatment Effects in Event Studies with Heterogeneous Treatment Effects},
  journal = {Journal of Econometrics},
  year    = {2021},
  volume  = {225},
  number  = {2},
  pages   = {175--199}
}
```

2) **Inference with few treated groups (Conley & Taber)**
```bibtex
@article{ConleyTaber2011,
  author  = {Conley, Timothy G. and Taber, Christopher R.},
  title   = {Inference with {D}ifference in {D}ifferences with a Small Number of Policy Changes},
  journal = {Review of Economics and Statistics},
  year    = {2011},
  volume  = {93},
  number  = {1},
  pages   = {113--125}
}
```

3) **Cluster-robust inference guidance (Cameron & Miller)**
```bibtex
@article{CameronMiller2015,
  author  = {Cameron, A. Colin and Miller, Douglas L.},
  title   = {A Practitioner's Guide to Cluster-Robust Inference},
  journal = {Journal of Human Resources},
  year    = {2015},
  volume  = {50},
  number  = {2},
  pages   = {317--372}
}
```

4) **Wild cluster bootstrap for few clusters (MacKinnon & Webb)**
```bibtex
@article{MacKinnonWebb2017,
  author  = {MacKinnon, James G. and Webb, Matthew D.},
  title   = {Wild Bootstrap Inference for Wildly Different Cluster Sizes},
  journal = {Journal of Applied Econometrics},
  year    = {2017},
  volume  = {32},
  number  = {2},
  pages   = {233--254}
}
```

5) **Pre-testing / event-study pitfalls (Roth)**
```bibtex
@article{Roth2022,
  author  = {Roth, Jonathan},
  title   = {Pre-test with Caution: Event-Study Estimates after Testing for Parallel Trends},
  journal = {American Economic Review: Papers and Proceedings},
  year    = {2022},
  volume  = {112},
  pages   = {305--309}
}
```

### Endogeneity / alternative designs you mention but don’t operationalize
If you want to claim synthetic control / SDID as future work, you should cite:
```bibtex
@article{AbadieDiamondHainmueller2010,
  author  = {Abadie, Alberto and Diamond, Alexis and Hainmueller, Jens},
  title   = {Synthetic Control Methods for Comparative Case Studies: Estimating the Effect of {C}alifornia's Tobacco Control Program},
  journal = {Journal of the American Statistical Association},
  year    = {2010},
  volume  = {105},
  number  = {490},
  pages   = {493--505}
}
```
```bibtex
@article{ArkhangelskyEtAl2021,
  author  = {Arkhangelsky, Dmitry and Athey, Susan and Hirshberg, David A. and Imbens, Guido W. and Wager, Stefan},
  title   = {Synthetic Difference-in-Differences},
  journal = {American Economic Review},
  year    = {2021},
  volume  = {111},
  number  = {12},
  pages   = {4088--4118}
}
```

### Domain/policy literature
The paper currently relies heavily on descriptive/case-study sources (e.g., Minnesota evaluation reports). For AEJ:EP or a top-5, you need to engage the broader health workforce and access literature (scope-of-practice expansions, mid-level providers, Medicaid dental policy, provider supply). I am not listing specific dental-therapy empirical papers here because your draft does not provide enough to verify which ones you already reviewed, but you should add:
- studies on **mid-level provider scope-of-practice** affecting access/prices,
- **Medicaid dental adult coverage** changes and utilization,
- and any peer-reviewed evaluations of dental therapy or closely related models (tribal DHAT programs, etc.).

---

# 5. WRITING QUALITY (CRITICAL)

### Prose vs bullets
- Mostly readable and organized, but the paper still reads like a **policy working paper** rather than a top-journal article.
- Convert key bullet lists (scope of practice; identification threats) into narrative paragraphs with mechanisms and citations.

### Narrative flow
- The motivation is clear, but the “hook” could be stronger: the paper’s contribution is essentially “first quasi-experimental population-level estimate with staggered DiD.” That is not enough for general interest unless the identification is exceptionally compelling (it isn’t yet).

### Accessibility and magnitudes
- You report −1.3 pp. You should also translate this into:
  - implied number of adults affected (back-of-the-envelope),
  - baseline mean (you do: ~65–67%),
  - and whether this is large relative to typical year-to-year changes.

### Tables/Figures as stand-alone objects
- Figure 2 should report exact coefficients somewhere (appendix table).
- Figure 3 needs redesign for legibility.

---

# 6. CONSTRUCTIVE SUGGESTIONS (How to make this publishable)

## A. Fix the biggest threat: 2020/COVID
1. **Re-estimate dropping 2020** (use 2012–2018 only). If the sign flips or attenuates sharply, the current finding is not interpretable as policy effect.
2. Include controls for **COVID policy intensity** (shutdown stringency, dental office restrictions) or use a design that absorbs pandemic shocks (hard with state-level aggregates and only 5 periods).

## B. Use annual microdata, not biennial aggregates
- The BRFSS dental visit question is available in many years. Using **annual BRFSS microdata** would:
  - increase periods (power, pre-trends),
  - allow Minnesota to contribute (pre-2009),
  - allow subgroup analysis (rural/low-income/insurance),
  - properly use BRFSS survey weights and consistent measurement.

## C. Measure treatment as *implementation*, not authorization
- Collect dates for:
  - first licensing rules effective,
  - first training program opening,
  - first dental therapist licensed/practicing (counts per state-year).
- Then estimate effects of **therapist supply per capita** (continuous treatment) or an adoption that starts when practice is feasible.

## D. Inference upgrades (essential)
- Report **wild cluster bootstrap p-values** (state clusters).
- Consider **randomization inference / permutation tests**:
  - randomly assign adoption years among adopter states,
  - or use placebo adoption among never-adopters.

## E. Stronger identification strategies
Given endogeneity concerns, consider:
- **Synthetic DiD (Arkhangelsky et al.)** for early adopters with better pre-period support.
- **Augmented synthetic control** for case-study states (ME, VT).
- A **triple-difference** using within-state variation if you can observe where therapists can practice (e.g., shortage areas, Medicaid-participating clinics, tribal areas) and compare to non-eligible areas.

## F. Outcomes closer to mechanisms
Dental visits are broad and may not move quickly. Add:
- unmet dental need due to cost,
- dental ED visits (HCUP state ED data if feasible),
- preventive vs restorative utilization (claims data in Medicaid states, if accessible),
- outcomes for targeted groups (Medicaid adults/children, rural residents).

---

# 7. OVERALL ASSESSMENT

### Key strengths
- Important policy question with genuine public finance/health relevance.
- Correctly avoids TWFE pitfalls and uses Callaway–Sant’Anna.
- Appropriately cautious interpretation; acknowledges endogeneity and lags.

### Critical weaknesses
- **Underpowered and under-identified time series** (5 periods; weak pre-trends).
- **2020/COVID confounding** is likely first-order and not addressed.
- **Authorization ≠ implementation**; treatment mismeasurement is severe.
- **Inference with few treated clusters** needs wild bootstrap / randomization inference.
- Paper is **too short** and reads like a working paper rather than a top-journal contribution.

### What would change my view
If you (i) move to annual microdata with longer pre-periods, (ii) show robustness excluding 2020, (iii) measure implementation and/or therapist supply, and (iv) upgrade inference, then the project could become credible and potentially impactful—especially if you can demonstrate meaningful effects (or credible nulls) for underserved subpopulations.

---

DECISION: REJECT AND RESUBMIT